Latest Recruitment News

Deterra Royalties has added a sizeable future copper income stream through its US$74.15 million Santa Cruz royalty acquisition, even as September-quarter revenue fell 15% year on year. The portfolio is gaining depth, but its next growth phase depends on construction, financing and commissioning milestones still ahead.

Tissue Repair has increased its US Phase III chronic wound trial to approximately 112 randomised patients while shifting focus towards an April 2027 FDA 510(k) submission. The company also reported $4.74 million in cash, Australian availability of all three TR Pro+ formats and a planned $1 million share buy-back.

Xref reported A$4.7 million of unaudited Q1 FY2027 revenue and positive EBITDA of A$0.6 million, as its newer platform generated 48% revenue growth. Trust Marketplace checks, Pulse surveys and employee lifecycle products all recorded sharp increases, while stronger liquidity is supporting renewed marketing investment.

Emyria has reported record quarterly revenue of approximately $1.42 million after opening its first Sydney Empax clinic and expanding national treatment capacity. The growth comes with $2.28 million in operating cash outflows and an estimated 2.08 quarters of funding at quarter-end.

BlinkLab has reported 82% sensitivity and 83% specificity from an exploratory ADHD study in 208 children, while preparing a US regulatory program for a second product. Its autism diagnostic remains on track for pivotal study completion this quarter, with A$16.2 million in cash at 30 September.

Dimerix has more than doubled its cash balance after an Everest Medicines licensing payment and a drawdown from a secured funding facility. The ASX-listed biotech is also advancing its fully recruited Phase 3 trial while preparing a second kidney drug for Phase 2 testing.

AoFrio’s nine-month revenue fell 20% to NZ$50.3 million as motor sales plunged, while EBITDA dropped to NZ$0.8 million. The NZX-listed refrigeration technology company is relying on new US bottler orders, Food Retail expansion and its IoT platform to support a more profitable 2027.

PainChek is concentrating its commercial effort on residential aged care after signing new US and UK business, including an 808-licence Sabra expansion and an approximately 1,800-licence Hallmark contract. Revenue and retention improved, but activated ARR growth slowed to 1.2% for the quarter and cash covered an estimated 2.5 quarters of historical operating outflows.

Element 25 has completed the enabling works for its planned 1.1Mtpa Butcherbird manganese expansion, moving the project towards major plant construction. Financial close on the AU$50 million NAIF package remains unfinished, leaving funding and contract finalisation as the next key tests.

Avecho has resumed recruitment for the final cohort of its pivotal Phase III insomnia trial after an interim review supported continuing at the original 519-participant target. The biotechnology company is also pursuing international licensing while holding $5.3 million in cash.

4DMedical reported a record first quarter, with scan volumes up 61% to 119,672 and unaudited operating revenue rising 66% to $2.3 million. New contracts across the US, Germany and Australia broaden the commercial story, while $242.8 million in cash gives the company room to keep investing.

South Port has entered FY27 with record full-year earnings behind it and first-quarter cargo volumes still rising, while a new chair takes over during a fresh investment cycle. The port is also preparing to add staff and potentially replace major equipment as regional development opportunities build.